Anaeropharma Science (Japan) pioneers the development of novel therapeutics based on its core platform technology, i-DPS, utilizing recombinant bifidobacterium. The technology has the potential for broad applications in oncology as well as other diseases related to hypoxic lesions.
Anaeropharma’s goal is to create more effective and safer therapeutics based on its core platform technology, i-DPS. The technology has the potential for broad applications in oncology as well as other diseases related to hypoxic lesions, taking advantage of characteristic features of Bifidobacterium, nonpathogenic obligate anaerobe constituting human gut flora, which only survives in hypoxic environment such as inside of solid tumor. The technology offers the potential of being more effective to solid tumors and generates oncology the drugs with less risks of adverse events than conventional anti-cancer drugs. The company aims to leverage the i-DPS technology to create a new class of anti-cancer drugs. The leading project is undertaking phase 1 clinical trial at three clinical sites in the U.S.